Efficacy and Safety of Levocabastine Nasal Spray for Seasonal Allergic Rhinitis
American Journal of Rhinology · 1999-01 · 13 (1) · 55-62
DOI: 10.2500/105065899781389867 ↗Kurz gefasst
Klinische Studie in der Zeitschrift American Journal of Rhinology, online erschienen am 01.01.1999. Verfasst von F C Hampel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Central Texas Health Research, New Braunfels 78130, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
This multicenter, double-blind, placebo-controlled trial evaluated the efficacy and safety of levocabastine nasal spray, a potent and selective H 1 -receptor antagonist, in the control of histamine-mediated symptoms of seasonal allergic rhinitis. Adults with ≥2 year history of allergic rhinitis due to Mountain Cedar were randomized to treatment with levocabastine nasal spray (0.2 mg twice daily) or placebo for 28 days during the 1994–1995 Mountain Cedar allergy season. Patients assessed the severity of their rhinitis symptoms on a four-point scale twice daily. At the end of the trial, patients also performed a global evaluation of treatment efficacy on a five-point scale. Overall for the 4-week treatment period, levocabastine nasal spray significantly reduced major nasal (runny nose and sneezing) and primary rhinitis (runny nose, sneezing, and itchy/gritty eyes) symptoms compared with placebo on both repeated measures (p = 0.023; p = 0.01) and ANOVA (p = 0.003; p < 0.001) analyses. Global evaluations of treatment efficacy at the end of the trial significantly favored levocabastine over placebo (p = 0.002). Overall, the incidence of adverse events was similar for both treatment groups. In general, most adverse events were mild in intensity, with sinusitis (17% each group), headache (17% placebo, 14% levocabastine), and rhinitis (8% placebo, 2% levocabastine) most commonly reported. Levocabastine nasal spray 0.2 mg twice daily was significantly more effective than placebo in the relief of histamine-mediated symptoms in patients with seasonal allergic rhinitis and was well tolerated over the 28-day treatment period.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Central Texas Health Research, New Braunfels 78130, USA.
Zitieren
APA
Hampel, F. C., Martin, B. G., Dolen, J., Travers, S., Karcher, K., & Holton, D. (1999). Efficacy and Safety of Levocabastine Nasal Spray for Seasonal Allergic Rhinitis. American Journal of Rhinology, 13(1), 55-62. https://doi.org/10.2500/105065899781389867
Vancouver
Hampel FC, Martin BG, Dolen J, Travers S, Karcher K, Holton D. Efficacy and Safety of Levocabastine Nasal Spray for Seasonal Allergic Rhinitis. American Journal of Rhinology. 1999;13(1):55-62. doi:10.2500/105065899781389867
BibTeX
@article{Hampel1999,
author = {Hampel, F C and Martin, B G and Dolen, J and Travers, S and Karcher, K and Holton, D},
title = {Efficacy and Safety of Levocabastine Nasal Spray for Seasonal Allergic Rhinitis},
journal = {American Journal of Rhinology},
year = {1999},
volume = {13},
number = {1},
pages = {55--62},
doi = {10.2500/105065899781389867}
}
EUVIMED